🇺🇸 FDA
Patent

US 7846892

Compositions and methods for Alzheimer's disease

granted A61KA61K2039/505A61P

Quick answer

US patent 7846892 (Compositions and methods for Alzheimer's disease) held by Primex Clinical Laboratories, Inc. expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Primex Clinical Laboratories, Inc.
Grant date
Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61P, A61P25/28